Literature DB >> 32776313

Open-label non-mandatory transitioning from originators to biosimilars in routine clinical care.

Giuseppe Provenzano1, Chiara Arcuri2, Maria Concetta Miceli2.   

Abstract

Keywords:  Ankylosing spondylitis; Biologic therapy; Biosimilar drugs; Psoriatic arthritis; Rheumatoid arthritis

Mesh：

Substances：

Year:  2020        PMID： 32776313     DOI： 10.1007/s10067-020-05327-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  1 in total

1.  Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect.

Authors:  Vincent Germain; Marc Scherlinger; Thomas Barnetche; Thierry Schaeverbeke
Journal:  Ann Rheum Dis       Date:  2018-10-23       Impact factor: 19.103
  1 in total
  1 in total

1.  Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review.

Authors:  Rosanne W Meijboom; Helga Gardarsdottir; Toine C G Egberts; Thijs J Giezen
Journal:  BioDrugs       Date:  2021-12-06       Impact factor: 5.807
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.